Navigation Links
Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
Date:11/5/2007

the integrity of the extracellular matrix. Excessive MMP activity has been demonstrated to occur in the liver in response to a variety of acute and chronic insults. This results in the loss of scaffolding that maintains the normal architecture of the liver and the recruitment and activation of inflammatory cells that perpetuate liver damage. In addition, important cytokines in the progression of liver damage, such as TGF-beta, stimulate the expression of MMPs from hepatic stellate cells, the main cell type involved in the pathology of fibrosis. MMPs are also well recognized to play an important and direct role in regulating inflammation. These dual activities of tissue remodeling and modulating inflammatory networks make MMPs an attractive target in the setting of acute and chronic liver disease.

Conatus Pharmaceuticals Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease. Chronic liver disease affects millions of people worldwide and can be caused by many different conditions or "insults" to the liver including Hepatitis C and other viral infections, obesity, chronic alcohol abuse or autoimmune diseases. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the successful sale of Idun to Pfizer.

http://www.conatuspharma.com


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015   Regulus Therapeutics ... leading the discovery and development of innovative medicines targeting ... and highlights for the quarter ended March 31, 2015 ... markets close. Regulus will host a ... at 5:00 pm Eastern Daylight Time to discuss its ...
(Date:4/30/2015)... (Nasdaq: NKTR ) today reported its financial results ... Cash and investments in marketable securities at ... $262.8 million at December 31, 2014. Our cash and ... a $100.0 million milestone payment received from AstraZeneca in ... in the U.S. "The recent U.S. launch ...
(Date:4/30/2015)... CARLSBAD, Calif. , April 30, 2015 /PRNewswire/ ... today it has earned a $10 million milestone ... an undisclosed target to treat a neurological disorder.  ... includes four drugs in development, under Isis, and ... novel therapies to treat neurological and neuromuscular disorders.  ...
Breaking Medicine Technology:Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 2Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 3Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 4Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 5Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 6Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 7Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 8Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 9Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 10Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 11Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 12Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen 2Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen 3
... BOSTON, Nov. 2 Schering-Plough Corporation (NYSE: SGP ... Phase IIa study of narlaprevir (SCH 900518), its investigational, ... patients with chronic hepatitis C virus (HCV) genotype 1. ... which patients received a 4-week lead-in of PEGINTRON(R) (peginterferon ...
... HCA has announced that Richard M. Bracken will become chairman ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20050825/CLTH069LOGO ) ... who will retire from the company, effective that same date. ... executive vice president, was elected to the board of directors, ...
Cached Medicine Technology:Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 2Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 3Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 4Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 5Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 6Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 7Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 8Bracken to Become Chairman of HCA's Board of Directors Effective Dec. 15 2
(Date:5/3/2015)... “ BolehVPN ” was featured on NewsWatch ... latest and coolest technology products available to consumers. Scott Steinberg, ... review and shared with viewers how to protect their private ... is on computers and even more so online. It helps ... all over the world. In terms of work, the internet ...
(Date:5/3/2015)... 03, 2015 It is not too late to ... Walk in Memory of Lissa Anne Been in Arnold, Missouri ... great family-friendly event to honor her loving memory. It has benefited ... , Just having turned 37, Lissa suffered a brain aneurysm ... August 24, 2012. This event is designed to serve as a ...
(Date:5/2/2015)... 2015 Vancouver fencing company, QS Fencing, has ... advice to prospective clients related to their questions on railings ... railings around their decks and patios. While that seems like ... up once the person rolls up their sleeve to start ... railing in finding a gate that matches it. , Instead ...
(Date:5/2/2015)... We are pleased to announce the ... as one of the Top Workplaces of 2015. , ... treatment field for their ethics and standards of excellence. ... continue their educational efforts. The Delray Recovery Center prides ... their purpose – to help individuals heal from the ...
(Date:5/2/2015)... 2015 As a nonsurgical staple ... the face, neck and décolleté, radiofrequency energy is ... potential for the success of vulvovaginal rejuvenation. In ... Advisory Council, ThermiGyn’s Women’s Health Clinical Advisory Board ... that ThermiGyn’s temperature controlled radio frequency, specifically that ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3
... Pharmaceuticals Inc. today,announced the appointment of Anthony "Tony" ... the recently initiated Phase 2 clinical trial of,CTS-1027 ... assisting in the,development of the longer-term clinical development ... more than 20 years in the,industry. Previous industrial ...
... Massey Cancer Center will open a Phase I ... with leading researchers from Israel, marking the first ... their counterparts in Israel. , The study ... U.S.-Israel Bi-National Industrial Research and Development Foundation (BIRDF). ...
... A free white paper is helping,building owners ... can result when they,re forced by the construction,schedule ... "system final,completion.", "There,s a disturbing trend in ... after occupancy," says Mike Della Barba,Director of Commissioning ...
... Social Security at http://www.nasi.org , WASHINGTON, March ... to comment on the implications of the,2008 Social Security ... listed below are members of the National Academy,of Social ... up of the nation,s leading,experts on Social Security, Medicare, ...
... Healthy,Coffee USA, Inc., the marketing arm of ... that Jim Clayton, a multi-level,marketing expert and start-up ... consultant. Mr. Clayton brings to the company a ... Clayton is a,start-up specialist who has been engaged ...
... of dying increased for patients with the common condition, ... Older people with heart failure face heightened odds of ... largest study ever conducted on the issue. , "We,re ... lead researcher Dr. Adrian F. Hernandez, an assistant professor ...
Cached Medicine News:Health News:Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer 2Health News:VCU Massey Cancer Center to partner with Israeli biotech firm 2Health News:VCU Massey Cancer Center to partner with Israeli biotech firm 3Health News:White Paper Helps Building Owners Avoid Costs, Downfalls of Construction Projects 2Health News:NASI Experts Available to Comment on 2008 Social Security and Medicare Trustees Reports 2Health News:NASI Experts Available to Comment on 2008 Social Security and Medicare Trustees Reports 3Health News:MLM Expert and Start-Up Specialist Jim Clayton Joins Healthy Coffee USA 2Health News:MLM Expert and Start-Up Specialist Jim Clayton Joins Healthy Coffee USA 3Health News:Heart Failure Raises Risks After Non-Cardiac Surgeries 2Health News:Heart Failure Raises Risks After Non-Cardiac Surgeries 3
... accurate portable, waterproof system for pH, mV (ORP), ... results can be obtained when used with a ... This GLP/GMP compliant system includes an RS-232 interface ... Up to 100 data sets can be stored ...
... 3 swing doors, 12 shelves. Over-sized compressor. ... Fluorescent interior lighting. Self-Contained System No plumbing ... Full One Year Warranty on Parts & ... Compressor. Also available as a chromatography ...
... shelves.Over-sized compressor. Triple pane thermal glass. ... System No plumbing required. Equipped with a ... on Parts & Labor and an Additional 4 ... as a chromatography unit which includes two access ...
... 1 swing door 4 shelves. ... Self-closing doors. Fluorescent interior lighting. Self-Contained ... 9 foot cord. Full One Year Warranty ... Year Warranty on Compressor. Also available ...
Medicine Products: